Cargando…

MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines

Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed...

Descripción completa

Detalles Bibliográficos
Autores principales: Skok, Kristijan, Gradišnik, Lidija, Čelešnik, Helena, Milojević, Marko, Potočnik, Uroš, Jezernik, Gregor, Gorenjak, Mario, Sobočan, Monika, Takač, Iztok, Kavalar, Rajko, Maver, Uroš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749978/
https://www.ncbi.nlm.nih.gov/pubmed/35011679
http://dx.doi.org/10.3390/cells11010117
_version_ 1784631356363374592
author Skok, Kristijan
Gradišnik, Lidija
Čelešnik, Helena
Milojević, Marko
Potočnik, Uroš
Jezernik, Gregor
Gorenjak, Mario
Sobočan, Monika
Takač, Iztok
Kavalar, Rajko
Maver, Uroš
author_facet Skok, Kristijan
Gradišnik, Lidija
Čelešnik, Helena
Milojević, Marko
Potočnik, Uroš
Jezernik, Gregor
Gorenjak, Mario
Sobočan, Monika
Takač, Iztok
Kavalar, Rajko
Maver, Uroš
author_sort Skok, Kristijan
collection PubMed
description Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed morphological and molecular characterisation and a comprehensive comparison with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence microscopy were used for morphological studies; immunocytochemical staining for hormone receptor, p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUM-BrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile; quantifiable morphological properties; and genetic stability up to (at least) the 6th passage.
format Online
Article
Text
id pubmed-8749978
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87499782022-01-12 MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines Skok, Kristijan Gradišnik, Lidija Čelešnik, Helena Milojević, Marko Potočnik, Uroš Jezernik, Gregor Gorenjak, Mario Sobočan, Monika Takač, Iztok Kavalar, Rajko Maver, Uroš Cells Article Triple-negative breast cancer (TNBC) is a breast cancer (BC) subtype that accounts for approximately 15–20% of all BC cases. Cancer cell lines (CLs) provide an efficient way to model the disease. We have recently isolated a patient-derived triple-negative BC CL MFUM-BrTNBC-1 and performed a detailed morphological and molecular characterisation and a comprehensive comparison with three commercial BC CLs (MCF-7, MDA-MB-231, MDA-MB-453). Light and fluorescence microscopy were used for morphological studies; immunocytochemical staining for hormone receptor, p53 and Ki67 status; RNA sequencing, qRT-PCR and STR analysis for molecular characterisation; and biomedical image analysis for comparative phenotypical analysis. The patient tissue-derived MFUM-BrTNBC-1 maintained the primary triple-negative receptor status. STR analysis showed a stable and unique STR profile up to the 6th passage. MFUM-BrTNBC-1 expressed EMT transition markers and displayed changes in several cancer-related pathways (MAPK, Wnt and PI3K signalling; nucleotide excision repair; and SWI/SNF chromatin remodelling). Morphologically, MFUM-BrTNBC-1 differed from the commercial TNBC CL MDA-MB-231. The advantages of MFUM-BrTNBC-1 are its isolation from a primary tumour, rather than a metastatic site; good growth characteristics; phenotype identical to primary tissue; complete records of origin; a unique identifier; complete, unique STR profile; quantifiable morphological properties; and genetic stability up to (at least) the 6th passage. MDPI 2021-12-30 /pmc/articles/PMC8749978/ /pubmed/35011679 http://dx.doi.org/10.3390/cells11010117 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Skok, Kristijan
Gradišnik, Lidija
Čelešnik, Helena
Milojević, Marko
Potočnik, Uroš
Jezernik, Gregor
Gorenjak, Mario
Sobočan, Monika
Takač, Iztok
Kavalar, Rajko
Maver, Uroš
MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title_full MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title_fullStr MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title_full_unstemmed MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title_short MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines
title_sort mfum-brtnbc-1, a newly established patient-derived triple-negative breast cancer cell line: molecular characterisation, genetic stability, and comprehensive comparison with commercial breast cancer cell lines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749978/
https://www.ncbi.nlm.nih.gov/pubmed/35011679
http://dx.doi.org/10.3390/cells11010117
work_keys_str_mv AT skokkristijan mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT gradisniklidija mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT celesnikhelena mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT milojevicmarko mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT potocnikuros mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT jezernikgregor mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT gorenjakmario mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT sobocanmonika mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT takaciztok mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT kavalarrajko mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines
AT maveruros mfumbrtnbc1anewlyestablishedpatientderivedtriplenegativebreastcancercelllinemolecularcharacterisationgeneticstabilityandcomprehensivecomparisonwithcommercialbreastcancercelllines